AI Bias Analysis
4 models · Takes ~15 seconds
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial
Source
Stat News
Opens original article in a new tab
Kyle Diamantas doesn't have the typical CV for an FDA commissioner, but he's earning early praise.
Medicaid cuts stemming from Republicans' 2025 tax law are expected to be even bigger than forecast.
(MedPage Today) -- Senior officials in the FDA's tobacco center were blindsided by a recent decision that opens the door to allowing more unauthorized electronic cigarettes and nicotine pouches onto the U.S. market, the Associated Press has learned...
(MedPage Today) -- Children and adolescents with Tourette syndrome had a lower risk of relapses with investigational ecopipam, a phase III randomized withdrawal study showed. Compared with placebo, ecopipam reduced relapse risk in 90 pediatric...
